Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (351-360 of 740) with videos related to

Pageof 74
Sort By:
Aging Cell|October 19, 2022
Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicityEleni-Dimitra Papanagnou, Sentiljana Gumeni, Aimilia D Sklirou, et al.
British Journal of Haematology|March 14, 2022
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemiaPolyxeni Delaporta, Evangelos Terpos, Elena E Solomou, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
International Journal of Cancer|January 17, 2019
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaEvangelos Terpos, Eirini Katodritou, Argiris Symeonidis, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|November 7, 2019
Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven ProcessLoula Papageorgiou, Kutaiba Alhaj Hussen, Sandrine Thouroude, et al.
Blood|January 5, 2022
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapyEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
British Journal of Haematology|November 22, 2018
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myelomaShaji K Kumar, Norbert Grzasko, Sosana Delimpasi, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
American Journal of Hematology|January 13, 2015
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Pageof 74

Showing results (351-360 of 740) with videos related to

Sort By:
Pageof 74
Aging Cell|October 19, 2022
Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicityEleni-Dimitra Papanagnou, Sentiljana Gumeni, Aimilia D Sklirou, et al.
British Journal of Haematology|March 14, 2022
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemiaPolyxeni Delaporta, Evangelos Terpos, Elena E Solomou, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
International Journal of Cancer|January 17, 2019
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myelomaEvangelos Terpos, Eirini Katodritou, Argiris Symeonidis, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|November 7, 2019
Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven ProcessLoula Papageorgiou, Kutaiba Alhaj Hussen, Sandrine Thouroude, et al.
Blood|January 5, 2022
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapyEvangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, et al.
British Journal of Haematology|November 22, 2018
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myelomaShaji K Kumar, Norbert Grzasko, Sosana Delimpasi, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
American Journal of Hematology|January 13, 2015
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Pageof 74